US Penny Stocks: 3 Picks With Market Caps Under $300M

In This Article:

As U.S. markets recently took a pause from a rally, optimism around corporate earnings and AI development continues to shape investor sentiment. In this context, penny stocks—often smaller or newer companies—can present unique opportunities for investors looking beyond the major indices. Despite their vintage name, these stocks can offer surprising value when supported by solid financials and growth potential.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$128.29M

★★★★★★

BAB (OTCPK:BABB)

$0.8562

$6.22M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.83

$11.49M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.97

$2.18B

★★★★☆☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.2874

$10.58M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.85

$86.45M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$3.47

$60.21M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.32

$23.41M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8902

$80.06M

★★★★★☆

Click here to see the full list of 706 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

ProKidney

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing a proprietary cell therapy platform for treating chronic kidney diseases in the United States, with a market cap of approximately $220.11 million.

Operations: ProKidney Corp. does not currently report any revenue segments as it is a clinical-stage biotechnology company.

Market Cap: $220.11M

ProKidney Corp., a clinical-stage biotech firm with a market cap of US$220.11 million, remains pre-revenue, focusing on innovative cell therapies for chronic kidney diseases. Despite its unprofitability and high share price volatility, the company boasts strong financial health with short-term assets of US$430.2 million exceeding liabilities and no debt burden. Recent regulatory updates highlight promising developments in its Phase 3 trial strategy for rilparencel, potentially paving the way for accelerated FDA approval pathways. However, management's relative inexperience could pose challenges as it navigates these complex clinical and regulatory landscapes while working towards profitability.

NasdaqCM:PROK Financial Position Analysis as at Jan 2025
NasdaqCM:PROK Financial Position Analysis as at Jan 2025

Performant Healthcare

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Performant Healthcare, Inc. offers technology-enabled payment integrity, eligibility, and analytics services with a market cap of approximately $190.25 million.